Blood Product Use for Hemorrhage during Cesarean Delivery
American Journal of Perinatology · 2026-11 · 43 (15) · 2006-2010
DOI: 10.1055/a-2859-5641 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Perinatology, online erschienen am 06.05.2026. Verfasst von Luis D Pacheco und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas, United States. Hauptthemen laut MEDLINE: Cesarean Section, Postpartum Hemorrhage, Blood Loss, Surgical, Blood Component Transfusion. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Abstract (Originalsprache)
Postpartum hemorrhage (PPH) remains a leading cause of maternal morbidity and mortality. Little is known about transfusion practices in patients requiring blood tansfusions following cesarean delivery. The objective of this study is to describe the use of blood products, clotting factors, colloids, and antifibrinolytics in a contemporary cohort of patients with hemorrhage during cesarean and compare blood product use with a historic cohort of patients with a similar diagnosis. Secondary analysis of a multicenter trial of tranexamic acid versus placebo to prevent PPH during cesarean delivery. Patients with qualitative estimated intraoperative blood loss (EBL) of more than 1 L were included in this analysis. Variables analyzed included transfusion of blood products, ratio of transfused packed red blood cell (PRBC) to fresh frozen plasma (FFP) and platelets, and use of clotting factors, anti-fibrinolytics, and colloids. Transfusion strategies were also compared with a historic cohort from the APEX study. Of the 707 (7.7%) who had EBL of greater than 1 liter, packed red cells were transfused in 21.1%, FFP in 5.4%, platelets in 2.4%, and cryoprecipitate in 2.3%. Among patients who received both PRBC and FFP, three quarters had a PRBC:FFP ratio between 1:1 and 2:1. Patients receiving both PRBC and platelets had a 1:1 ratio or less in 76.5% of cases. Clotting factor concentrates were not used in any case. Albumin was administered in 10.2% of cases. When compared with the historic cohort with an EBL > 1 L during cesarean, no differences in the use of blood products was noted. 1 in 5 patients with intraoperative EBL > 1 L received PRBC transfusion. The use of other blood products was rare. There was no difference in transfusion strategies overtime when compared with a similar historic cohort. Obstetrical hemorrhage in patients undergoing cesarean delivery rarely involves intensive transfusion therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas, United States.
- Biostatistics Center, The George Washington University, Washington, District of Columbia, United States.
- Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania, United States.
- Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.
- Division of Extramural Research, Pregnancy and Perinatology Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland, United States.
- Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, United Kingdom.
Förderung
- NICHD NIH HHS
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
Zitieren
APA
Pacheco, L. D., Weiner, S. J., Saade, G. R., Clifton, R. G., Parry, S., Thorp, J. M., Longo, M., Salazar, A., Tita, A. T. N., Gyamfi-Bannerman, C., Chauhan, S. P., Metz, T. D., Rood, K., Rouse, D. J., Bailit, J. L., Grobman, W. A., Simhan, H. N., Macones, G. A., & Eunice Kennedy Shriver National Institute of Child Health Human Development Maternal-Fetal Medicine Units (MFMU) Network (2026). Blood Product Use for Hemorrhage during Cesarean Delivery. American Journal of Perinatology, 43(15), 2006-2010. https://doi.org/10.1055/a-2859-5641
Vancouver
Pacheco LD, Weiner SJ, Saade GR, Clifton RG, Parry S, Thorp JM, et al. Blood Product Use for Hemorrhage during Cesarean Delivery. American Journal of Perinatology. 2026;43(15):2006-2010. doi:10.1055/a-2859-5641
BibTeX
@article{Pacheco2026,
author = {Pacheco, Luis D and Weiner, Steven J and Saade, George R and Clifton, Rebecca G and Parry, Samuel and Thorp, John M and Longo, Monica and Salazar, Ashley and Tita, Alan T N and Gyamfi-Bannerman, Cynthia and Chauhan, Suneet P and Metz, Torri D and Rood, Kara and Rouse, Dwight J and Bailit, Jennifer L and Grobman, William A and Simhan, Hyagriv N and Macones, George A and Eunice Kennedy Shriver National Institute of Child Health Human Development Maternal-Fetal Medicine Units (MFMU) Network, Eunice Kennedy Shriver National Institute of Child Health Human Development Maternal-Fetal Medicine Units (MFMU) Network},
title = {Blood Product Use for Hemorrhage during Cesarean Delivery},
journal = {American Journal of Perinatology},
year = {2026},
volume = {43},
number = {15},
pages = {2006--2010},
doi = {10.1055/a-2859-5641}
}
EUVIMED